As of Jul 02
| -0.02 / -0.11%|
The 5 analysts offering 12-month price forecasts for Trinity Biotech PLC have a median target of 25.00, with a high estimate of 30.00 and a low estimate of 21.00. The median estimate represents a +37.14% increase from the last price of 18.23.
The current consensus among 6 polled investment analysts is to Buy stock in Trinity Biotech PLC. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.